Shanghai Pharma IPO yields $2B

Shanghai Pharmaceuticals wrapped up its IPO in Hong Kong at a price of HK$23 per share, or almost $2 billion total. Pfizer was a key investor with $50 million in the deal. The stock will start trading on Friday. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.